文献速递妇科

维拉普生治疗子宫肌瘤女性:随机2b期ASTEROID 1研究

Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study.
PubMed 文献 · Fertil Steril · 2018-12-07

这项随机、双盲、安慰剂对照、多中心试验在12国98中心纳入309例子宫肌瘤伴月经过多女性,评估维拉普生0.5–4.0 mg每日一次口服12周的安全性和疗效。维拉普生1.0–4.0 mg组无出血/点滴出血比例达54%–60%,安慰剂组为1.7%;≥1.0 mg组>83%达到闭经(<2 mL/28天),安慰剂组为9%。

要点

  • 维拉普生1.0、2.0、4.0 mg组完全无出血/点滴出血比例分别为56%、54%、60%,安慰剂组1.7%。
  • ≥1.0 mg维拉普生组>83%达到闭经(<2 mL/28天),安慰剂组为9%。
  • 子宫肌瘤体积最大缩小41%,多数患者症状严重程度改善。

核心结论

  • ASTEROID 1支持维拉普生治疗子宫肌瘤相关月经过多的疗效。
  • 维拉普生0.5–4.0 mg每日一次口服耐受性良好,已选择维拉普生2.0 mg每日一次进一步研究。

研究设计与样本

  • 随机、双盲、安慰剂对照、多中心试验,在12国98个中心开展。
  • 309例18–50岁子宫肌瘤伴月经过多女性随机等比分入维拉普生0.5、1.0、2.0、4.0 mg或安慰剂每日一次口服组,300例接受治疗。
  • 治疗12周,随访24周。

主要发现

  • 完全无计划内或计划外出血/点滴出血的比例在维拉普生0.5、1.0、2.0、4.0 mg组分别为30%、56%、54%、60%,安慰剂组为1.7%。
  • 治疗12周后,≥1.0 mg维拉普生组>83%女性达到闭经(<2 mL/28天),安慰剂组为9%。
  • ≥1.0 mg维拉普生治疗后月经过多停止,但停药后以较低血量恢复。
  • 观察到子宫肌瘤体积最大缩小41%。
  • 多数接受维拉普生的患者报告症状严重程度改善。

关键数值与推荐

  • 主要终点为无计划内或计划外出血/点滴出血。
  • 关键次要疗效终点包括月经失血量容积和子宫肌瘤体积变化。
  • 在一般安全性、子宫内膜安全性(经活检)、实验室值和超声检查中未发现安全性问题。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the safety and efficacy of four vilaprisan doses (0.5-4.0 mg) in women with uterine fibroids. DESIGN: Randomized, double-blind, placebo-controlled, multicenter trial. SETTING: Ninety-eight centers in 12 countries. PATIENT(S): Women aged 18-50 years with uterine fibroids and heavy menstrual bleeding were randomized equally to oral vilaprisan at 0.5, 1.0, 2.0, or 4.0 mg or placebo once daily. INTERVENTION(S): Treatment for 12 weeks, 24-week follow-up. MAIN OUTCOME MEASURE(S): Primary end point was absence of scheduled or unscheduled bleeding/spotting. Key secondary efficacy end points included volume of menstrual blood loss and change in fibroid volume. RESULT(S): A total of 309 patients were randomized, and 300 received treatment. Complete absence of bleeding/spotting was observed in 30%, 56%, 54%, and 60% of patients in the vilaprisan 0.5, 1.0, 2.0, and 4.0 mg groups, respectively, versus 1.7% with placebo. After 12 weeks, >83% of women achieved amenorrhea (<2 mL/28 days) with ≥1.0 mg vilaprisan versus 9% with placebo. Heavy menstrual bleeding stopped (but returned at a lower volume after treatment cessation) with ≥1.0 mg vilaprisan treatment. Reductions in fibroid volume of up to 41% were observed. Most patients receiving vilaprisan reported improvements in symptom severity. No safety concerns were identified in general safety, endometrial safety (by biopsy), laboratory values, and ultrasound examinations. CONCLUSION(S): ASTEROID 1 supports the efficacy of vilaprisan for the treatment of heavy menstrual bleeding associated with uterine fibroids. Daily oral treatment with vilaprisan 0.5-4.0 mg was well tolerated, and vilaprisan 2.0 mg once daily has been selected for further investigation. CLINICAL TRIAL REGISTRATION NUMBER: NCT02131662.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Bradley LD, Singh SS, Simon J, et al. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study. Fertil Steril. 2018. PMID: 30527839. doi:10.1016/j.fertnstert.2018.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。